Chemclin Diagnostics Co., Ltd. engages in the research and development, production, and sale of clinical immune chemiluminescence diagnostic reagents and instruments. Its products include LiCAA series of diagnostic reagents based on photo-induced chemiluminescence and CC series based on enzymatic chemiluminescence diagnostic reagents and instruments, primarily used for infectious diseases, such as hepatitis B, hepatitis C, AIDS, syphilis, hepatitis A, hepatitis E, etc.; and detection of tumor markers, thyroid hormones, reproductive endocrine hormones, cardiac markers, and inflammation. The company was founded in 2007 and is headquartered in Beijing, China.
Frequently asked questions
What sector does Chemclin Diagnostics Co. Ltd. A (688468) operate in?
Chemclin Diagnostics Co. Ltd. A belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is Chemclin Diagnostics Co. Ltd. A (688468) current stock price?
As of the latest data, Chemclin Diagnostics Co. Ltd. A stock price is CN¥6.23, with a previous close of CN¥6.23.
What is Chemclin Diagnostics Co. Ltd. A (688468) current market capitalization?
Chemclin Diagnostics Co. Ltd. A market cap is approximately 2.50 billion.
What is Chemclin Diagnostics Co. Ltd. A (688468) Earnings Per Share (EPS)?
The trailing EPS is CN¥0.09.
What is Chemclin Diagnostics Co. Ltd. A (688468) Price-to-Earnings (P/E) ratio?
Chemclin Diagnostics Co. Ltd. A current P/E ratio is 69.22.
Does Chemclin Diagnostics Co. Ltd. A (688468) pay dividends?
No. Chemclin Diagnostics Co. Ltd. A does not pay a dividend.
What is Chemclin Diagnostics Co. Ltd. A (688468) beta (volatility) score?
Chemclin Diagnostics Co. Ltd. A has a beta of 0.066, indicating lower volatility than the overall market.
